A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 2,487,800 shares of GILD stock, worth $220 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
2,487,800
Previous 6,255,700 60.23%
Holding current value
$220 Million
Previous $429 Million 51.42%
% of portfolio
0.5%
Previous 0.98%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$66.59 - $83.99 $251 Million - $316 Million
-3,767,900 Reduced 60.23%
2,487,800 $209 Million
Q2 2024

Aug 14, 2024

BUY
$63.15 - $72.88 $74.3 Million - $85.7 Million
1,176,100 Added 23.15%
6,255,700 $429 Million
Q1 2024

May 15, 2024

BUY
$71.58 - $87.29 $280 Million - $341 Million
3,910,300 Added 334.41%
5,079,600 $372 Million
Q4 2023

Feb 14, 2024

SELL
$73.27 - $83.09 $186 Million - $211 Million
-2,542,500 Reduced 68.5%
1,169,300 $94.7 Million
Q3 2023

Nov 14, 2023

SELL
$73.94 - $80.67 $19.9 Million - $21.7 Million
-268,500 Reduced 6.75%
3,711,800 $278 Million
Q2 2023

Aug 14, 2023

SELL
$76.01 - $86.7 $95.5 Million - $109 Million
-1,256,100 Reduced 23.99%
3,980,300 $307 Million
Q1 2023

May 15, 2023

BUY
$77.31 - $88.08 $14.7 Million - $16.7 Million
189,900 Added 3.76%
5,236,400 $434 Million
Q4 2022

Feb 14, 2023

SELL
$62.32 - $89.47 $50.9 Million - $73 Million
-816,000 Reduced 13.92%
5,046,500 $433 Million
Q3 2022

Nov 14, 2022

BUY
$59.54 - $68.01 $20.5 Million - $23.4 Million
344,800 Added 6.25%
5,862,500 $362 Million
Q2 2022

Aug 15, 2022

BUY
$57.72 - $65.01 $53 Million - $59.7 Million
918,800 Added 19.98%
5,517,700 $341 Million
Q1 2022

May 16, 2022

BUY
$57.92 - $72.58 $66.9 Million - $83.9 Million
1,155,800 Added 33.57%
4,598,900 $273 Million
Q4 2021

Feb 14, 2022

SELL
$64.88 - $73.64 $83.3 Million - $94.6 Million
-1,284,000 Reduced 27.16%
3,443,100 $250 Million
Q3 2021

Nov 15, 2021

BUY
$67.69 - $73.03 $318 Million - $344 Million
4,704,199 Added 20541.46%
4,727,100 $330 Million
Q2 2021

Aug 16, 2021

BUY
$63.47 - $69.35 $1.45 Million - $1.59 Million
22,901 New
22,901 $1.58 Million
Q4 2020

Feb 16, 2021

SELL
$56.65 - $64.55 $328,570 - $374,390
-5,800 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$62.1 - $78.08 $7.48 Million - $9.41 Million
-120,470 Reduced 95.41%
5,800 $367,000
Q2 2020

Aug 14, 2020

SELL
$72.34 - $84.0 $2.18 Million - $2.53 Million
-30,069 Reduced 19.23%
126,270 $9.72 Million
Q1 2020

May 15, 2020

SELL
$62.63 - $80.22 $191 Million - $245 Million
-3,056,101 Reduced 95.13%
156,339 $11.7 Million
Q4 2019

Feb 14, 2020

SELL
$61.62 - $67.78 $91.9 Million - $101 Million
-1,491,900 Reduced 31.71%
3,212,440 $209 Million
Q3 2019

Nov 14, 2019

SELL
$62.51 - $69.0 $33.2 Million - $36.7 Million
-531,300 Reduced 10.15%
4,704,340 $298 Million
Q2 2019

Aug 14, 2019

BUY
$61.87 - $69.38 $82.2 Million - $92.2 Million
1,328,600 Added 34.01%
5,235,640 $354 Million
Q1 2019

May 15, 2019

BUY
$62.53 - $70.05 $175 Million - $196 Million
2,802,200 Added 253.63%
3,907,040 $254 Million
Q4 2018

Feb 14, 2019

BUY
$60.54 - $79.0 $62.4 Million - $81.5 Million
1,031,502 Added 1406.5%
1,104,840 $69.1 Million
Q3 2018

Nov 14, 2018

SELL
$71.28 - $78.92 $1.25 Million - $1.39 Million
-17,600 Reduced 19.35%
73,338 $5.66 Million
Q2 2018

Aug 14, 2018

SELL
$64.88 - $75.68 $3.86 Million - $4.5 Million
-59,499 Reduced 39.55%
90,938 $6.44 Million
Q1 2018

May 15, 2018

SELL
$72.84 - $88.8 $43.6 Million - $53.1 Million
-598,145 Reduced 79.9%
150,437 $11.3 Million
Q4 2017

Feb 14, 2018

SELL
$71.15 - $83.52 $182 Million - $214 Million
-2,558,687 Reduced 77.37%
748,582 $53.6 Million
Q3 2017

Nov 14, 2017

BUY
$72.11 - $85.47 $238 Million - $283 Million
3,307,269
3,307,269 $268 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $111B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.